Literature DB >> 27291156

Processing of miR17-92 Cluster in Hepatic Stellate Cells Promotes Hepatic Fibrogenesis During Alcohol-Induced Injury.

Elizabeth Brandon-Warner1, Nicole A Feilen1, Catherine R Culberson1, Conroy O Field1, Andrew S deLemos2, Mark W Russo2, Laura W Schrum1.   

Abstract

BACKGROUND: Exposure to alcohol and its metabolites can initiate hepatic injury and fibrogenesis. Fibrosis is mediated through hepatic stellate cell (HSC) activation, leading to global changes in mRNA and microRNA (miR) expression. miRs are expressed in cells or shuttled to exosomes which can be detected in tissue culture media (TCM) and biological fluids. The mechanisms and function underlying the differential expression and processing of miRs and their downstream effects during hepatic injury remain poorly understood.
METHODS: Expression of primary (pri)-miR17-92. and individual members of this cluster, miR17a, 18a, 19a, 20a, 19b, and 92, were examined in primary HSCs and human LX2 cells exposed to alcohol-conditioned media (CM), liver tissue from a rodent model of alcoholic injury, and in exosomes from TCM and plasma of rodent models and patients with alcoholic liver disease (ALD). miR expression was examined in HSCs transduced with an AAV2 vector carrying GFP-miR19b or GFP-control transgene under the collagen promoter.
RESULTS: Profibrotic markers were enhanced in primary HSCs and LX2 cells exposed to alcohol-CM, concomitant with decreased miR19b expression and a significant increase in pri-miR17-92. Increased pri-miR17-92 was confirmed in a rodent model of alcohol-induced liver injury. Individual members of the cluster were inversely proportionate in cells and exosomes. AAV2-mediated miR19b overexpression inhibited miR17-92 and altered expression of individual cluster members in cells and exosomes. Expression of individual miR17-92 cluster members in plasma exosomes isolated from patients with ALD was similar to that seen in a rodent model of alcoholic injury and in vitro.
CONCLUSIONS: Reintroduction of miR19b inhibits HSC activation and modulates expression of pri-miR17-92 and the inverse expression of individual cluster members in cells and exosomes. Better understanding of miR17-92 processing may provide mechanistic insights into the role of individual miRs and exosomes during hepatic injury, revealing new therapeutic targets.
Copyright © 2016 by the Research Society on Alcoholism.

Entities:  

Keywords:  Alcohol; Exosomes; Fibrosis; Hepatic Stellate Cells; Liver; MicroRNA; miR19b

Mesh:

Substances:

Year:  2016        PMID: 27291156      PMCID: PMC4930422          DOI: 10.1111/acer.13116

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  50 in total

1.  Chronic ethanol feeding accelerates hepatocellular carcinoma progression in a sex-dependent manner in a mouse model of hepatocarcinogenesis.

Authors:  Elizabeth Brandon-Warner; Tracy L Walling; Laura W Schrum; Iain H McKillop
Journal:  Alcohol Clin Exp Res       Date:  2011-10-21       Impact factor: 3.455

Review 2.  microRNAs: fad or future of liver disease.

Authors:  Ashley M Lakner; Herbert L Bonkovsky; Laura W Schrum
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

3.  Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice.

Authors:  Takahiro Kodama; Tetsuo Takehara; Hayato Hikita; Satoshi Shimizu; Minoru Shigekawa; Hinako Tsunematsu; Wei Li; Takuya Miyagi; Atsushi Hosui; Tomohide Tatsumi; Hisashi Ishida; Tatsuya Kanto; Naoki Hiramatsu; Satoshi Kubota; Masaharu Takigawa; Yoshito Tomimaru; Akira Tomokuni; Hiroaki Nagano; Yuichiro Doki; Masaki Mori; Norio Hayashi
Journal:  J Clin Invest       Date:  2011-07-11       Impact factor: 14.808

4.  Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha.

Authors:  Brandi N Davis; Aaron C Hilyard; Peter H Nguyen; Giorgio Lagna; Akiko Hata
Journal:  Mol Cell       Date:  2010-08-13       Impact factor: 17.970

5.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

Review 6.  Targeting microRNAs in obesity.

Authors:  Huangming Xie; Lei Sun; Harvey F Lodish
Journal:  Expert Opin Ther Targets       Date:  2009-10       Impact factor: 6.902

7.  S-adenosyl-L-methionine attenuates oxidative stress and hepatic stellate cell activation in an ethanol-LPS-induced fibrotic rat model.

Authors:  Amel Karaa; Kyle J Thompson; Iain H McKillop; Mark G Clemens; Laura W Schrum
Journal:  Shock       Date:  2008-08       Impact factor: 3.454

8.  MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure.

Authors:  Geert C van Almen; Wouter Verhesen; Rick E W van Leeuwen; Mathijs van de Vrie; Casper Eurlings; Mark W M Schellings; Melissa Swinnen; Jack P M Cleutjens; Marc A M J van Zandvoort; Stephane Heymans; Blanche Schroen
Journal:  Aging Cell       Date:  2011-05-25       Impact factor: 9.304

Review 9.  TGF-β in progression of liver disease.

Authors:  Steven Dooley; Peter ten Dijke
Journal:  Cell Tissue Res       Date:  2011-10-19       Impact factor: 5.249

10.  MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis.

Authors:  Jelena Mann; David C K Chu; Aidan Maxwell; Fiona Oakley; Nian-Ling Zhu; Hidekazu Tsukamoto; Derek A Mann
Journal:  Gastroenterology       Date:  2009-10-17       Impact factor: 22.682

View more
  17 in total

1.  Adeno-Associated Virus Serotype 2 Vector-Mediated Reintroduction of microRNA-19b Attenuates Hepatic Fibrosis.

Authors:  Elizabeth Brandon-Warner; Jennifer H Benbow; Jacob H Swet; Nicole A Feilen; Catherine R Culberson; Iain H McKillop; Andrew S deLemos; Mark W Russo; Laura W Schrum
Journal:  Hum Gene Ther       Date:  2018-03-01       Impact factor: 5.695

Review 2.  Extracellular Vesicles: Intercellular Mediators in Alcohol-Induced Pathologies.

Authors:  Mohammad A Rahman; Benjamin J Patters; Sunitha Kodidela; Santosh Kumar
Journal:  J Neuroimmune Pharmacol       Date:  2019-04-06       Impact factor: 4.147

Review 3.  Pathological Contribution of Extracellular Vesicles and Their MicroRNAs to Progression of Chronic Liver Disease.

Authors:  Chanbin Lee; Jinsol Han; Youngmi Jung
Journal:  Biology (Basel)       Date:  2022-04-21

Review 4.  Extracellular vesicles in inflammation: Focus on the microRNA cargo of EVs in modulation of liver diseases.

Authors:  Mrigya Babuta; Gyongyi Szabo
Journal:  J Leukoc Biol       Date:  2021-11-10       Impact factor: 6.011

Review 5.  Exosomes as therapeutic vehicles in liver diseases.

Authors:  Jingyi Ding; Ju Wang; Jiajia Chen
Journal:  Ann Transl Med       Date:  2021-04

6.  Hepatic stellate cell-derived exosomes modulate macrophage inflammatory response.

Authors:  Jennifer H Benbow; Emilio Marrero; Rachel M McGee; Elizabeth Brandon-Warner; Neha Attal; Nicole A Feilen; Catherine R Culberson; Iain H McKillop; Laura W Schrum
Journal:  Exp Cell Res       Date:  2021-05-26       Impact factor: 4.145

Review 7.  Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives.

Authors:  Szu-Yi Liu; I-Ting Tsai; Yin-Chou Hsu
Journal:  Int J Mol Sci       Date:  2021-05-13       Impact factor: 5.923

Review 8.  Extracellular Vesicles in NAFLD/ALD: From Pathobiology to Therapy.

Authors:  Alejandra Hernández; Juan Pablo Arab; Daniela Reyes; Ainhoa Lapitz; Han Moshage; Jesús M Bañales; Marco Arrese
Journal:  Cells       Date:  2020-03-27       Impact factor: 6.600

Review 9.  Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease.

Authors:  Jorge-Luis Torres; Ignacio Novo-Veleiro; Laura Manzanedo; Lucía Alvela-Suárez; Ronald Macías; Francisco-Javier Laso; Miguel Marcos
Journal:  World J Gastroenterol       Date:  2018-09-28       Impact factor: 5.742

Review 10.  Exosomal microRNAs as diagnostic and therapeutic biomarkers in non-malignant liver diseases.

Authors:  Seonghwan Hwang; Yoon Mee Yang
Journal:  Arch Pharm Res       Date:  2021-06-24       Impact factor: 4.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.